Abstract. In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. pNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.

Epidemiological studies showed that pancreatic neuroendocrine tumors (pNETs) are rare cancers with an incidence of less than 1 per 100,000 persons per year, representing 1-2% of all pancreatic neoplasms in Europe (1). However, in recent years, an increase of pNETs’ incidence has been registered probably because of a better identification of these tumors due to the improvement of pathologic and diagnostic techniques (2). It is fundamental, in order to indicate the most appropriate therapy, a clear identification of the pNETs’ origin, grading, as well as presence and localization of metastases. To date, this is possible by acquiring data from laboratory tests, histology and radiologic imaging (3, 4). Biopsy of the tumor is the first fundamental step to achieve an appropriate diagnosis and classification of pNET, including immunocytochemical staining to determine eventual secretion of substances (“secreting” pNETs). Thus, the first important discrimination is between well-differentiated (low or intermediate grade) or poorly differentiated (high-grade) tumors (6).

On a clinical point of view, some types of pNETs are asymptomatic and indolent and may grow at a very low rate for several years before displaying symptoms; other types can rapidly progress determining disability and worsening of quality of life (7).

If the tumor is identified in early, localized stage, radical surgery is the gold standard treatment (8). Unfortunately, hepatic
metastases are present at diagnosis in about 10% of pNETs; approximately 85% of patients will develop hepatic metastases during a follow-up period of 20 years (9). Surgical resection of metastases is still possible in 10% of patients with liver disease with a 4-year survival rate of 73% with major hepatic resections (9) and acceptable morbidity (10). In addition to surgery, medical oncologic intervention is recommended by the most important guidelines (European Society for Medical Oncology, North American Neuroendocrine Tumor Society) in order to control hormone-dependent symptoms and to improve survival (11) (Figure 1).

Actually, in the well-differentiated, metastatic or non-resectable disease, clinical studies have demonstrated that target systemic therapies may represent a new interesting opportunity for patients with advanced pNETs (12). This review article will focus on new antiangiogenic therapies in pNETs and will highlight unresolved issues of this research area, such as choice of medications in different tumor stages, effectiveness of combination of different antiangiogenic agents, duration and scheduling of therapy and mechanism(s) of resistance. In the future, research is needed to improve the identification of the key regulators of angiogenesis in different phases of pNETs and develop a progressively personalized antiangiogenic therapy.

### Tumor Angiogenesis

Angiogenesis is the development of new blood vessels from pre-existing ones; it is crucial in wound healing, embryogenesis, and normal tissue growth. However, as cancer develops through the angiogenesis process, a tumor can grow only if it is able to build new vessels from the surrounding environment (13). This process works both in local development and in metastatic spread. Notably, pNETs are highly vascularized neoplasms. This characteristic is associated with the overexpression of both ligand and related receptor of vascular endothelial factor (VEGF) (14), particularly in hepatic metastases (15). VEGF is a key driver of the metastatic process of pNETs (16) and, therefore, a pharmaceutical treatment against this pathway should be an interesting therapeutic option for patients with advanced disease. Furthermore, pNETs also show strong expression of platelet-derived growth factor receptors (PDGFRs) α and β, as well as stem-cell factor receptor (c-kit). Recent advances in the understanding of pNETs micro-environment biology make these receptors an interesting target for antiangiogenic treatment (17). We will focus on the role of bevacizumab and sunitinib as potential effective therapeutic options (Figure 2).

### Pancreatic Neuroendocrine Tumors’ Medical Treatment

PNETs represent a group of rare neoplasms that originate from pancreatic endocrine cells (18). Surgery is the gold-standard treatment in localized disease (19); when curative or radical surgery is not possible, other medical options are available with the intent to decrease tumor proliferation, slow tumor progression and control tumor symptoms. The therapeutic management is determined by many factors: histology, metastatic sites, patient’s condition. Ideally, the drugs with the most appropriate pharmacological profile should be determined for each single patient. In secreting pNETs presenting with specific symptoms, the disease should be controlled using analogues of somatostatin that simulate its biological action by binding to related receptors. Somatostatin analogues (SAs), in addition to providing symptoms’ control, block or slow tumor cells’ proliferation, both by direct binding of specific receptors and by decreasing the availability of growth factors (20). To date, there are two synthetic SAs with proven efficacy and safety: octreotide and lanreotide (21, 22). The only chemotherapeutic drug with solid evidence-based medical data in advanced pNETs is streptozotocin, an alkylating agent of the nitrosourea class of compounds, that induces damage in DNA and cell death (apoptosis and necrosis) (23). Other types of chemotherapy did not show a clear advantage compared to streptozotocin.

### Angiogenesis Inhibitors to Treat pNETs

**Bevacizumab.** Vascular endothelial growth factor (VEGF) is a heparin-binding glycoprotein that stimulates angiogenesis in numerous tumors; it has been demonstrated that the inhibition of the VEGF pathway represents an effective antiangiogenic therapy in cancer (24). Bevacizumab is a recombinant human IgG1 monoclonal antibody that specifically binds VEGF in the bloodstream and blocks binding to its receptors expressed by tumor cells and vascular endothelial cells; it reduces the vessel density and, thus, the interstitial pressure around the tumor mass ameliorates the delivery of pharmacologically active molecules to tumor site (25). Its efficacy has been also demonstrated in an in vitro model of pNETs (26). Bevacizumab showed anti-tumor activity and efficacy both in monotherapy and in combination with interferon in metastatic renal cell carcinoma (27) or chemotherapy in metastatic colorectal cancer (28), lung (29) and breast (30) cancer, thus obtaining the approval by pharmaceutical authorities.

In neuroendocrine tumors, bevacizumab was recently tested in a phase II study in forty-five metastatic well-/moderately differentiated NETs. The treatment consisted of a combination of octreotide long-acting release (LAR) 20 mg per month intramuscularly (i.m.), capecitabine 2,000 mg per os (p.o.) per day (metronomic scheme) and bevacizumab intravenously (i.v.) (5 mg/kg) every two weeks for 36 weeks; bevacizumab was administered until disease progression. The
treatment was well-tolerated and partial responses were observed in 8 patients (response rate: 17.8%) with a median progression-free survival (PFS) of 14.9 months. Interestingly, the best results were obtained in pancreatic malignancies (31).

Several clinical trials are ongoing to investigate efficacy and safety of bevacizumab in association with other agents in pNETs (32). Bevacizumab was also recently tested in association with temozolomide in a phase II study. Among 34 patients enrolled, the overall response rate was 15%; interestingly, responses were registered only in patients affected by pNETs, none in other carcinomas. The median PFS was 11 months: 14.3 months in pNET versus 7.3 months in other carcinomas. The median overall survival (OS) was 33.3 months: 41.7 months in pNET versus 18.8 months in other carcinomas (33). Thus, encouraging results have been obtained in selected advanced pNETs, however, in other cases, the responses were short in duration or the disease was clearly resistant. The explanation can be partially found in an important preclinical study; the VEGF-targeted molecules suppress the growth of new vessels, but the action against stable tumor vasculature was much less intense (34). Furthermore, in early phases of cancer progression, the tumor’s new blood vessels are more dependent on the VEGF pathway, a dependency, however, that, in later phases, is reduced or completely lost, thus leaving space to other angiogenic drivers to gain the scene (35). In fact, other factors, such as platelet-derived growth factors (PDGFs), contribute to the angiogenic process by mediating the

Figure 1. Management of pancreatic neuroendocrine tumors (pNETs). TAE, transcatheter arterial embolization.

Figure 2. Bevacizumab and sunitinib inhibit the angiogenic cross-talk between pNET mass and local vasculature. Vascular endothelial growth factor (VEGF) and platelet-derived growth factors (PDGFs) are overexpressed by the pancreatic neuroendocrine tumors (pNETs) to produce new blood vessels for the growing mass; they bind to the their related receptors. Bevacizumab is a monoclonal antibody against VEGF preventing VEGF/VEGF-R interaction. Sunitinib is a small molecule that binds to and inhibits the intra-cellular tyrosine kinases’ domains associated to PDGFs receptors.
recruitment of pericytes to the neoplastic mass; the inhibition of PDGFs pathway enhances the efficacy of agents targeting VEGF (36).

Two phase III studies have been presented at ASCO 2015 (SWOG S0518 trial and the CALGB 80701 trial) but the results were disappointing. In the first trial, the association of depot octreotide with bevacizumab, in poor prognosis carcinoid patients, did not ameliorate the PFS compared to depot octreotide with interferon alpha-2b. In the CALGB 80701 trial patients affected by metastatic pNETs were randomized to receive octreotide LAR and everolimus+/-bevacizumab. Unfortunately, the association of bevacizumab with octreotide LAR did not show a significant gain in PFS.

The optimization of angiogenic therapy in pNETs is an open question; in particular, a clear clinical end-point has not been identified for bevacizumab therapy in this oncologic setting, as well as the complete spectrum of adverse events associated with its use.

**Sunitinib.** Sunitinib received approval for the treatment of many solid tumors (including renal cell carcinoma, gastrointestinal stromal tumors, NETs) on the basis of positive results in clinical studies (37, 38).

Basic research has demonstrated that many chemotherapy-resistant cancer cells show hyperactivity on a plethora of tyrosine kinases, including VEGF, KIT and PDGF. Sunitinib malate is a multi-target agent able to inhibit irreversibly many tyrosine kinases overexpressed in pNETs, including VEGF receptor 2 and 3, PDGFR α and β, stem-cell factor receptor, showing strong antitumor properties (39).

Sunitinib was successfully tested in phase I and II studies enrolling pNETs. In a phase II study on 66 pNETs patients treated with sunitinib at 50 mg daily for 4 weeks followed by 2 weeks of rest, a response rate of 16.7%, evaluated according to RECIST criteria, was reached, with 68.2% of patients showing stable disease for over 24 weeks (40). In a further phase II study, 12 patients with advanced well-differentiated pNETs were treated with a continuous daily dose of 37.5 mg. Six patients exhibited partial response and 3 stable disease (clinical benefit 75%, 95% confidence interval (CI)=42.8-94.5). In both studies, toxicity reported was consistent with the known safety profile of the drug.

In a recent multi-national, double-blind, randomized trial, the continuous schedule (sunitinib 37.5 mg daily) was compared to placebo in 171 patients affected by advanced, well-differentiated pNETs. The study was early discontinued for the clear advantage of sunitinib versus the placebo group. Median PFS for sunitinib was 11.4 months, for placebo 5.5 months (p<0.001); nine deaths occurred in the sunitinib (10%) versus 21 (25%) in the placebo group (42). Based on these results, sunitinib received approval for the treatment of locally advanced and/or metastatic pNETs.

**Sunitinib-Bevacizumab Association: The Clinical Results**

As sunitinib and bevacizumab block complementary angiogenic pathways, a possible therapeutic approach could be their association in order to potentiate the antitumor effects observed. A phase I exploratory study on the association between bevacizumab and sunitinib was conducted for many different malignancies (43). Interestingly, 7 out of 38 patients achieved a partial response (18%, 95% CI=8-34). However, grade 3 antiangiogenic-specific toxicities were observed: 47% grade 3 hypertension, 18% thrombocytopenia, 13% proteinuria.

Thus, a sequential strategy was proposed in order to reduce the toxic effects produced by their association (44). A multicenter, phase I clinical trial was conducted with sunitinib at 37.5 mg on days 1-28 and bevacizumab i.v. at 5 mg/kg on day 29 followed by 2 weeks of rest. Interestingly, 2 patients showed partial response, 3 stable disease. The study, however, was discontinued due to unacceptable toxicity; in fact, a patient suffered grade 1 microangiopathic hemolytic anemia; and, thus, the authors concluded that the association was nor safe neither recommendable. Furthermore, the study confirmed that, during antiangiogenic therapy with sunitinib, a compensatory production of VEGF is observed (“VEGF flare-up”). The mechanism underlying the VEGF flare-up is unknown; one of the hypotheses, however, is that VEGF could be a response of growing tumor cells and/or tumor’s microenvironment to the decrease of other pro-angiogenic factors. Nevertheless, these phenomena highlight the importance of a “dynamic” evaluation of the angiogenic background of the patients during therapy.

**Conclusion**

The recent advances in the comprehension of pNETs’ biology have prompted oncologists to investigate targeted therapies, particularly the pathways of somatostatin, VEGF and mammalian target of rapamycin. Considering the long survival of patients affected by advanced, well-differentiated neuroendocrine tumors, alternative strategies based on targeted therapies and new schedules (metronomic, alternate sequences, combinations of biologics, etc.) are justified.

As antiangiogenic therapies limit tumors’ growth and, clinically, the goal to completely cure cancer cannot be achieved, improvements of time-to-progression and/or OS appear reasonable for transforming cancer into a chronic condition. Consequently, these drugs should have a good toxicity profile and be administered on a long-term basis.

Basic research, aimed to clarify mechanisms of resistance and find markers of response, is necessary in the near future for designing more appropriate and personalized clinical trials.
Conflicts of Interest

All Authors declare that they have no conflict of interest.

Acknowledgements

The Authors would like to thank the non-profit organization Lega Italiana Per La Lotta Contro i Tumori (LILIT) of Naples, Italy.

References


32 Randomized phase ii study of everolimus alone versus everolimus plus bevacizumab in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (ongoing study ClinicalTrials.gov identifier NCT01229943).


